Q4 2024 Viking Therapeutics Inc Earnings Call Transcript
Key Points
- Viking Therapeutics Inc (VKTX) reported successful results from four different studies across its pipeline in 2024, including positive data from the VK2735 subcutaneous and oral tablet programs for obesity.
- The VK2809 program for the treatment of MASH and fibrosis achieved its primary, secondary, and exploratory endpoints, showing significant reductions in liver fat and improvements in MASH resolution rate and fibrosis.
- The company announced positive results from a Phase 1b clinical trial of VK0214 for X-linked adrenoleukodystrophy, demonstrating safety, tolerability, and significant reductions in plasma levels of very long chain fatty acids.
- Viking Therapeutics Inc (VKTX) closed a successful public offering of common stock, raising over $630 million, which bolstered its financial position with over $900 million in cash by the end of 2024.
- The company plans to initiate Phase 3 trials for VK2735 in obesity in the second quarter of 2025, indicating a clear path forward for its lead program.
- Viking Therapeutics Inc (VKTX) reported a net loss of $110 million for the year ended December 31, 2024, an increase from the $85.9 million loss in 2023, primarily due to increased research and development and administrative expenses.
- Research and development expenses rose significantly to $101.6 million in 2024 from $63.8 million in 2023, driven by increased manufacturing costs for drug candidates and stock-based compensation.
- General and administrative expenses also increased to $49.3 million in 2024 from $37 million in 2023, due to higher costs related to stock-based compensation, salaries, and professional fees.
- The company faces logistical challenges in manufacturing and preparing clinical materials for its Phase 3 trials, which could impact timelines.
- There is uncertainty regarding the recruitment timeline for the Phase 3 obesity studies, as the company has not yet provided guidance on patient enrollment duration.
Welcome to the Viking Therapeutics' fourth-quarter and full-year 2024 financial results conference call. (Operator Instructions)
As a reminder, this conference call is being recorded today, February 5, 2025.
I would now like to turn the conference over to Viking's Manager of Investor Relations, Stephanie Diaz. Please go ahead, Stephanie.
Hello and thank you all for participating in today's call. Joining me today is Brian Lian, Viking's President and CEO; and Greg Zante, Viking's CFO. Before we begin, I'd like to caution that comments made during this conference call today, February 5, 2025, will contain forward-looking statements under the Safe Harbor provisions of the US Private Securities Litigation Reform Act of 1995 including statements about Viking's expectations regarding its development activities, timelines, and milestones.
Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
